Kornimate/medical-research-clean huggingface dataset:
adenoma detection rate using endocuff vision in china

Conditions: Colorectal Neoplasms; Colonic Polyp; Adenoma

Summary: the primary aim of this study is - to explore the usefulness of endocuff vision in colonoscopy on adenoma detection rate (adr). other aims include to explore the data below when endocuff vision is used. mean adenomas detected per procedure, map proximal adenoma detection rate, padr polyp detection rate, pdr proximal polyp detection rate, ppdr mean polyps detected per procedure, mpp withdrawal time, wt cecal intubation rate, cir cecal intubation time, cit

colorectal cancer is common in china. most colorectal cancers happen when an adenoma becomes cancerous. doctors use colonoscopy to look inside the colon and rectum and find adenomas and remove them. removing adenomas is known to reduce the chances of a person developing colorectal cancers. the ability of colonoscopists finding adenomas varies, and there is a lot of researches into how to improve "adenoma detection rates". a new device, called the endocuff vision has been shown to improve the rate of polyp detection at colonoscopy, and to make polyp removal easier. previous studies have shown that there is a significant improvement in detection of adenomas when an endocuff vision is used (with the rate of detection of adenomas rising from 49% to 66%). colonoscopists who have used the endocuff vision before also feel that polyp removal is easier when it is on the colonoscope. this study will randomise patients coming for colonoscopy to have their procedure performed as usual or as an endocuff vision-assisted colonoscopy. the investigators will record polyp and adenoma detection rates, duration of procedure, participant comfort levels, and complications. all patients referred for colonoscopy will be invited in 5 centres, recruiting a total of 1200 participants.

Eligibility criteria:
inclusion criteria: * all patients referred for screening, surveillance, or diagnostic colonoscopy * all patients must be able to give informed consent exclusion criteria: * patients with any absolute contraindications to colonoscopy * patients with established or suspicion of large bowel obstruction or pseudo-obstruction * patients with known colon cancer or polyposis syndromes * patients with known colonic strictures * patients with known severe diverticular segments (that is likely to impede colonoscope passage) * patients with active colitis (ulcerative colitis, crohn's colitis, diverticulitis, infective colitis) * patients lacking capacity to give informed consent * pregnancy * patients who are on clopidogrel, warfarin, or other new generation anticoagulants who have not stopped this for the procedure. * patients who are attending for a therapeutic procedure or assessment of a known lesion

Keywords: adenoma detection rate
a study of capecitabine (xeloda®) and concomitant radiation therapy in children with newly diagnosed brainstem gliomas

Conditions: Brainstem Glioma

Summary: this study evaluated the effect of capecitabine and concomitant radiation therapy in children with newly diagnosed brainstem gliomas.

the open-label phase 2 study no21125 (nct01118377) evaluated the progression-free survival, safety, and pharmacokinetics of capecitabine (xeloda®) rapidly disintegrating tablets and concomitant radiation therapy in children and adolescent patients with newly diagnosed brainstem glioma. there were 2 phases to the study: a 9-week radiation phase, followed by a 2-week rest period, and a 9-week post-radiation phase. in the radiation phase, capecitabine 650 mg/m\^2 was administered orally twice daily for 9 weeks. concomitantly, patients received radiation therapy (180 cgy fractions) 5 days a week for a total target dose of 56 gy. during the 9-week post-radiation phase of the study, capecitabine 1250 mg/m\^2 was administered orally twice daily for 14 days followed by a 7-day rest period. this cycle of 14 days treatment followed by 7 days rest was repeated 2 additional times. the dose could be adjusted according to toxicity and body surface area. the single-arm phase 1 study no18517 (nct00532948) assessed the maximum tolerated dose and dose-limiting toxicities of capecitabine (xeloda®) administered concurrently with radiation therapy in children with newly diagnosed diffuse intrinsic brain stem gliomas and high grade gliomas. patients in the phase 1 study no18517 who were diagnosed with intrinsic brainstem glioma and who were treated at the established maximum tolerated dose of capecitabine 650 mg/m\^2/dose twice a day were included in the analyses of the phase 2 study no21125. the efficacy and safety results of study no21125 are reported below.

Eligibility criteria:
inclusion criteria: * pediatric and adolescent patients ≥ 3 to \< 18 years of age. * patients must have a newly diagnosed non-disseminated intrinsic infiltrating brainstem glioma. * karnofsky performance scale (if \> 16 years of age) or lansky performance score (if ≤ 16 years of age) ≥ 50% assessed within 2 weeks prior to registration to study. * patients must not have received any prior chemotherapy or bone marrow transplant for the treatment of brainstem glioma. prior dexamethasone and/or surgery are allowed. * adequate organ function. exclusion criteria: * patients receiving any other anticancer or experimental drug therapy. * patients with uncontrolled infection. * known dihydropyrimidine dehydrogenase (dpd) deficiency.
development and acceptability testing of ready-to-use-complementary food supplement (rucfs) for children in bangladesh

Conditions: Moderately Malnourished Children

Summary: the prevention of malnutrition among children under 5 years of age requires consumption of nutritious food, including exclusive breast feeding for the first six months of life, followed by breastfeeding in combination with complementary foods thereafter until at least 24 months of age; a hygienic environment; access to preventive as well as curative health services, and good prenatal care. the proposed research is on the possible options for providing a nutritious diet, realizing the constraints of poverty and food insecurity faced by care givers whose children are at risk of developing or confirmed to be suffering from moderate malnutrition. even when people are not typically food insecure but consume a relatively monotonous diet with few good-quality foods, they also have to have options for dietary improvement, and especially the possibility of ready-to-use complementary food supplements (rucfs) for young children. this proposed research on development of rucfs will pave the way for programmatic considerations for expansion of the use of new complementary food supplements for preventing malnutrition among young children in bangladesh.


Eligibility criteria:
inclusion criteria: * 6 to 18 months; either sex, having no acute illness, and be on at least one semi-solid or solid food in a day. exclusion criteria: * loss of appetite, * oral lesion, * congenital anomaly/acquired disorder affecting growth, * severe acute malnutrition (sam) defined by: * muac \< 115 mm or * wl \< -3 z score or * bipedal edema, * persistent diarrhea, * tuberculosis, * any other chronic illness.
radioactive iodide (131i) treatment of 124i pet/ct detected breast cancers

Conditions: Breast Cancer; Metastatic Breast Cancer

Summary: this is a treatment protocol designed to accompany the ongoing institutional 124i pet/ct pilot imaging study for patients with invasive breast cancer. women whose tumors express nis \[na+i- symporter, sodium iodide symporter\] and demonstrate radioiodide uptake on 124i pet/ct scans will be eligible for 131i treatment if, (1) tumor dosimetry calculations yield a cumulative radiation dose of at least 30gy in target tumor, (2) estimated cumulative thyroid irradiation is less than 500 cgy and, (3) the therapeutic dose of 131i is in the range of 25 to 100 mci.


Eligibility criteria:
inclusion criteria: * patients with measurable locally advanced or metastatic breast cancer who completed 124i pet/ct imaging study. * patients who are 18 years of age or older. * patients must have a life expectancy of at least 3 months. * i 124 dosimetry completed with thyroid dose to 500 cgy or less and tumor dose of 2500 cgy or more. * i131 therapeutic dose calculated from dosimetry. dose must be in a range of 25 to 150 mci. * patients with eastern cooperative oncology group (ecog) performance status 0-3 will be eligible. * use of concurrent systemic therapy (hormonal or cytotoxic) if associated with stable disease for at least three months prior to treatment. * women with locally advanced breast cancer and simultaneous metastases, even if surgery to eradicate local disease has taken place. * thyroid stimulating hormone (tsh) must be \< 0.4 uiu/ml. * white blood cell count \>= 1,500 and platelet count \>= 40,000 * women receiving thyroid hormone supplements and methimazole. * ability to understand and the willingness to sign a written informed consent document. * premenopausal women must use contraception while receiving this treatment and during follow-up period of 42 days. exclusion criteria: * stage 0-ii breast cancer. * pregnant or nursing women. * not able to sign informed consent. * untreated psychiatric disorder. * women who have not had i124 pet/ct scan and dosimetry calculations. * radioiodide uptake in non-target organs or bone marrow does not exceed 25 cgy by pre-treatment dosimetry. * received chemotherapy less than 4 weeks before. * history of thyroid cancer.
group b streptococcus (gbs) associated stillbirths in a high burden setting

Conditions: Stillbirth

Summary: this is a descriptive study to determine the role of fetal gbs disease as a cause for stillbirths

a prospective, descriptive study will be undertaken involving mothers who have a stillbirth at chris hani baragwanath academic hospital (chbah), a secondary-tertiary care hospital, from 2014 up until 2016.

Eligibility criteria:
inclusion criteria: * pregnant women delivering a stillbirth at chbah * participants aged ≥18 years * able to understand and comply with planned study procedures * provides written informed consent (either generic icf or v98_28obtp) exclusion criteria: * refuses to consent to study participation

Keywords: group b streptococcus, stillborn
light therapy to treat depression in pediatric stem cell therapy recipients

Conditions: Hematopoietic Stem Cell Transplant

Summary: the participants are being asked to be in this clinical trial, a type of research study, because the participants are going to have a hematopoietic stem cell transplant (hsct) in the near future. participants that get hsct's often get depression and/or suffer from depressive symptoms, tiredness, and sleep disturbances. primary objective to evaluate the efficacy of bl therapy for the treatment of depression in children and adolescents undergoing hematopoietic stem cell transplant. secondary objectives * to evaluate the temporal effect and magnitude of bl vs. dl therapy on depression in pediatric patients undergoing hsct. * to evaluate the efficacy of bl therapy for the treatment of fatigue in children and adolescents undergoing hematopoietic stem cell transplant. * to evaluate the response of bl therapy versus dl on sleep quality. exploratory objectives * to compare incidence of positive delirium screenings between those receiving bl therapy versus dl * to evaluate participant and caregiver perceptions of the acceptability, ease of use, and risks/benefits of the use of light therapy glasses during hsct utilizing qualitative interviews.

if you decide to be in this study, you will be asked to: * complete some surveys before the study begins * take more surveys for about 4 weeks * wear light therapy glasses for about 30 minutes each day for about 4 weeks * wear a wrist monitor every day and night for the 1st and last week of the study to record your motion and sleeping habits. * keep a ''sleep diary" where you will mark the times that you sleep while wearing the wrist monitor. * complete an optional interview at the end of the study.

Eligibility criteria:
inclusion criteria: * age ≥8 to \<18 years of age at the time of enrollment * allogeneic hsct planned to occur between 7 and 10 days in the future from recruitment * patient and/or primary caregiver reads and writes in english or spanish * participant/guardian is willing to sign informed consent * optional interview participants must be english speaking * baseline self-report of depressive symptoms on the promis® pediatric depressive symptoms v3.0 (promis-peddepsx) ≥ 55 exclusion criteria: * taking photosensitizing medications * total blindness / complete lack of light perception bilaterally * significant physiological or psychological impairment that interferes with participation * any patient that, in the opinion of the primary investigator is not appropriate for the study * inability or unwillingness of research participant or legal guardian/representative to give written informed consent. * non-english-speaking participants will not be eligible for the optional qualitative interview * baseline self-report of depressive symptoms on the promis® pediatric depressive symptoms v3.0 (promis-peddepsx) \< 55

Keywords: depression sleep fatigue
the evaluation of nitric oxide generating lozenges on outcome in newly diagnosed covid-19 patient of african american and hispanic origin

Conditions: COVID-19

Summary: this study is a multi-center, randomized, double blinded, prospective, placebo controlled study. patients upon diagnosis of covid-19 (corona virus disease-19) will be eligible to participate in the study. the purpose of this study is to find out the side effects and ability to take the study drug, nitric oxide (no) lozenges when taken twice daily by mouth. if this study shows that the drug has no or few, acceptable side effects, it will then include up to 840 participants to find out if the drug can reduce bad outcomes of covid-19 infection (hospitalization, icu admission, death). in each part of the study, half of the subjects will receive the study drug and the other half will be given a placebo (inactive pill).


Eligibility criteria:
inclusion criteria: 1. male or female of 50-85 years of age 2. subjects with recent covid-19 diagnosis (within 72 hours), that are symptomatic (fever, cough, sob, weakness, or other flu-like symptoms). 3. agrees to comply with study procedures (diary, oximeter readings, telephone follow up). 4. has given voluntary, written, informed consent to participate in the study. 5. identifies as african american or hispanic origin 6. patients must have at least 1 risk factor (history of hypertension (bp\> 140/99) chf, angina, prior mi, coronary angiography with one significantly occluded vessel, diabetes mellitus, obesity, or smoking, (for at least 5 years). exclusion criteria: 1. females who are pregnant, breastfeeding or planning to become pregnant during the course of the study. 2. patients unresponsive or unable to take anything by mouth (npo). 3. individuals who are cognitively impaired and/or who are unable to give informed consent. 4. blood pressure below 110 mmhg systolic and 60 mmhg diastolic on entry into study. 5. history of syncope or other symptoms of orthostatic hypotension. 6. history of methemoglobinemia. 7. severe case of g6pd deficiency
patient reported outcomes and patient education in cellular therapy patients

Conditions: Stem Cell Transplant; CAR T-Cell Transplant; CAR T-Cell Therapy; Cellular Therapy; Hematopoietic Stem Cell Transplant; HSCT; Multiple Myeloma; Leukemia; Lymphoma

Summary: the purpose of this research is to provide an educational visit addressing common emotional stressors involved in the transplant/car-t process, and determine if this added education improves levels of anxiety, depression, and fatigue after transplant/cart in comparison to people who do not receive the brief educational visit.

individuals who decide to participate in this study, will be provided with a survey evaluating current symptoms. this survey should take approximately 10 minutes to complete. individuals will then be scheduled for a 30 minute telephone visit to review common emotional stressors experienced after stem cell transplant/car-t therapy as well as strategies to help reduce these symptoms. participants will be provided with a pamphlet to review during the visit and independently afterwards. this visit will be conducted by telephone to avoid extra travel to the hospital, and will be conducted prior to admission for transplant/car-t. individuals will then be asked to fill out the same set of surveys at 1 month, 3 months, 6 months, and 12 months after receiving the transplant/car-t therapy. these surveys will be conducted during other scheduled clinic visits to avoid additional travel to the hospital. an individual's involvement will be complete at 1 year. if an individual receives post-transplant/car-t care at a hospital other than dhmc, surveys will be mailed to the participant to complete and return at the same time points.

Eligibility criteria:
inclusion criteria: * any patient with an underlying hematologic disease planning to undergo an autologous or allogeneic hematopoietic stem cell transplant (hsct) or chimeric antigen receptor t-cell (car-t) therapy at dartmouth-hitchcock medical center is eligible. * the patient must be approved for hsct/car-t by the treating transplant physician. this includes completion of their pre-treatment work up and consent as directed by the standard dhmc sops. - age \>18 years, and no upper age limit exclusion criteria: * any patient with medical, social, or psychological factors that would prevent the patient from cooperating with the trial and completing surveys at requested intervals.
clinic waiting room-based study of swahili language artificial intelligence-driven symptom assessments in tanzanian primary health care facilities

Conditions: Abdominal Pain/Gastrointestinal Issues; Lower Respiratory System Conditions; Upper Respiratory System Conditions; Mental Health Conditions; Ophthalmology Conditions; Orthopedic Conditions; Cardiovascular System Conditions; Genitourinary System Conditions; ENT Conditions; Dermatology Conditions; Gynecology/Obstetrics Conditions; Neurological Conditions

Summary: this study will evaluate the accuracy of the condition suggestions and urgency advice of the swahili language ada symptom assessment application (saa), when symptoms are input by a lay-person user and a medical professional; these saa results will then be compared to the condition suggestions and urgency advice of different tiers of doctors and a "gold standard" created by a panel.

there will be two different wings of this study: (1) where a lay-person inputs their symptoms into the swahili language ada symptom assessment application (saa); (2) where the usual care doctor asks a lay-person (the patient) the same questions from the saa and determines their own condition suggestions based off this questioning and the saa's condition suggestions. in both wings, the patient will be seeing their usual care doctor for a diagnosis and then a study-provided physician for a diagnosis. separately, the doctors will list a ranking of other considered condition suggestions (diagnoses) and urgency advice, which will not be shared with the patient. these condition suggestions and urgency advice will be compared to a "gold standard", which will be determined by a high level panel for each patient's case, based on the doctor notes and physical examination results of each patient's visit.

Eligibility criteria:
inclusion criteria: * all patients who enter the clinic and that are willing/able to provide consent will be included, except those who fall under certain conditions listed below exclusion criteria: * patients with severe injury/illness requiring immediate treatment * patients with traumatic injury (many of these patients require minimal anamnesis, and it is not rational to include them in a pilot study) * patients incapable of completing a health assessment (e.g. due to illiteracy, mental impairment or inebriation or other incapacity).
postoperation maintenance therapy for resectable liver metastases of colorectal cancer guided by ctdna

Conditions: Colorectal Cancer; Liver Metastases; Circulating Tumor Cell; Cancer, Therapy-Related

Summary: the goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.the main question it aims to answer is to investigate whether the progression-free survival (pfs) of resectable colorectal liver metastasis (crlm) patients with positive ctdna after surgery is superior with the combination of adjuvant chemotherapy and maintenance therapy compared to adjuvant chemotherapy alone.


Eligibility criteria:
inclusion criteria: 1. both males and females, aged 18-75 years; 2. patients with liver metastatic colorectal cancer who have undergone r0 resection based on mdt evaluation (including patients whose metastases have been treated with ablation achieving similar r0 resection effect); 3. postoperative ctdna-positive patients; 4. asa grade \< iv and/or ecog performance status score ≤ 2; 5. participants must have a full understanding of the study and voluntarily sign an informed consent form. exclusion criteria: 1. patients with distant metastases to other sites, including the pelvis, ovaries, peritoneum, etc. 2. patients with a history of other malignant tumors. 3. patients with severe liver or kidney dysfunction, cardiorespiratory dysfunction, coagulation dysfunction, or underlying diseases that cannot tolerate chemotherapy. 4. patients who are allergic to any component of the study. 5. patients who have received other tumor-related investigational drug treatments. 6. patients with severe uncontrolled recurrent infections or other severe uncontrolled accompanying diseases. 7. patients with other factors that may affect the study results or lead to early termination of the study, such as alcoholism, drug abuse, other serious diseases requiring comprehensive treatment (including mental illness), and severe laboratory abnormalities. 8. patients with a history of severe mental illness. 9. pregnant or lactating women. 10. patients who, in the opinion of the researchers, have other clinical or laboratory conditions that make them unsuitable for participation in the study.

Keywords: colorectal cancer liver metastases ctdna maintenance therapy
prescription opioid addiction treatment study (poats)

Conditions: Opiate Dependence; Substance-related Disorders; Opioid-related Disorders

Summary: the purpose of this study is to determine whether treatment outcome for subjects dependent on prescription opioid analgesics can be improved by adding individual drug counseling to the prescription of buprenorphine/naloxone with standard medical management. this will be examined during: a) an initial four-week treatment with taper; b) a 12-week stabilization treatment for those who do not respond successfully to the initial treatment; and c) a long-term follow-up assessment at 1.5 years, 2.5 years, and 3.5 years after treatment.

this is a randomized 2-phase, open-label; multi-center study conducted in outpatient treatment settings. the main objective of this study is to identify an effective sublingual buprenorphine/naloxone treatment regimen for subjects dependent on prescription opioids. phase 1 of this study will assess the prevailing one-month detoxification practice. this phase will assess the benefits of individual drug counseling in a short-term treatment paradigm. the second phase of this study will assess the benefit of individual drug counseling in a longer-term treatment paradigm for participants who did not respond successfully to the short-term buprenorphine/naloxone treatment. there is also a long-term follow-up assessment to determine outcomes at 1.5 years, 2.5 years, and 3.5 years after treatment.

Eligibility criteria:
inclusion criteria: * 18 years old or older * physically dependent on opioids * meet dsm-iv criteria for opioid dependence exclusion criteria: * known allergy or sensitivity to buprenorphine or naloxone * unstable psychiatric disorder * pregnant or lactating females * liver function test results greater than 5 times the upper limit of normal range

Keywords: opiate analgesic dependence